Literature DB >> 26264223

Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?

Gaya Spolverato1, Alessandro Vitale2, Alessandro Cucchetti3, Irinel Popescu4, Hugo P Marques5, Luca Aldrighetti6, T Clark Gamblin7, Shishir K Maithel8, Charbel Sandroussi9, Todd W Bauer10, Feng Shen11, George A Poultsides12, J Wallis Marsh13, Timothy M Pawlik1.   

Abstract

BACKGROUND: A patient can be considered statistically cured from a specific disease when their mortality rate returns to the same level as that of the general population. In the current study, the authors sought to assess the probability of being statistically cured from intrahepatic cholangiocarcinoma (ICC) by hepatic resection.
METHODS: A total of 584 patients who underwent surgery with curative intent for ICC between 1990 and 2013 at 1 of 12 participating institutions were identified. A nonmixture cure model was adopted to compare mortality after hepatic resection with the mortality expected for the general population matched by sex and age.
RESULTS: The median, 1-year, 3-year, and 5-year disease-free survival was 10 months, 44%, 18%, and 11%, respectively; the corresponding overall survival was 27 months, 75%, 37%, and 22%, respectively. The probability of being cured of ICC was 9.7% (95% confidence interval, 6.1%-13.4%). The mortality of patients undergoing surgery for ICC was higher than that of the general population until year 10, at which time patients alive without tumor recurrence can be considered cured with 99% certainty. Multivariate analysis demonstrated that cure probabilities ranged from 25.8% (time to cure, 9.8 years) in patients with a single, well-differentiated ICC measuring ≤5 cm that was without vascular/periductal invasion and lymph nodes metastases versus <0.1% (time to cure, 12.6 years) among patients with all 6 of these risk factors. A model with which to calculate cure fraction and time to cure was developed.
CONCLUSIONS: The cure model indicated that statistical cure was possible in patients undergoing hepatic resection for ICC. The overall probability of cure was approximately 10% and varied based on several tumor-specific factors. Cancer 2015;121:3998-4006.
© 2015 American Cancer Society. © 2015 American Cancer Society.

Entities:  

Keywords:  cure; hepatic resection; intrahepatic cholangiocarcinoma; surgery

Mesh:

Year:  2015        PMID: 26264223     DOI: 10.1002/cncr.29619

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

Review 1.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Budd Chiari Syndrome and Intrahepatic Cholangiocarcinoma, An Unusual Combination: Case Report and Review of the Literature.

Authors:  Anshuman Elhence; Shivanand Gamanagatti; Prasenjit Das
Journal:  Perm J       Date:  2020-11

3.  Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma.

Authors:  Grace C Lee; T Clark Gamblin; Zhi Ven Fong; Cristina R Ferrone; Lipika Goyal; Keith D Lillemoe; Lawrence S Blaszkowsky; Kenneth K Tanabe; Motaz Qadan
Journal:  Ann Surg Oncol       Date:  2019-07-31       Impact factor: 5.344

4.  Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis.

Authors:  Cristina Mosconi; Leonardo Solaini; Giulio Vara; Nicolò Brandi; Alberta Cappelli; Francesco Modestino; Alessandro Cucchetti; Rita Golfieri
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-11       Impact factor: 2.740

5.  Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-08-24       Impact factor: 3.452

6.  Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study.

Authors:  Xu-Feng Zhang; Jeffery Chakedis; Fabio Bagante; Eliza W Beal; Yi Lv; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

7.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

8.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  WAVE3 Induces EMT and Promotes Migration and Invasion in Intrahepatic Cholangiocarcinoma.

Authors:  Zebin Zhu; Wei Chen; Xiaoyu Yin; Jiaming Lai; Qian Wang; Lijian Liang; Wei Wang; Anxun Wang; Chaoxu Zheng
Journal:  Dig Dis Sci       Date:  2016-03-12       Impact factor: 3.199

10.  Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer.

Authors:  Gaya Spolverato; Fabio Bagante; Cecilia G Ethun; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Emily Winslow; Clifford Cho; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.